Analysis Of Antitumor Drugs At Home And Abroad

At present, China's antitumor drugs are numerous, different growth rate. Antineoplastic agents include anti-metabolic, plant, alkylating agents, antitumor antibiotics, platinum, hormones, monoclonal antibodies, protein kinase inhibitors, immunomodulators and traditional Chinese medicine preparations. In addition to immunization agents and other auxiliary drugs, the anti-metabolic preparations market share of the largest, more robust growth; plant market scale ranked second, the future can still maintain rapid growth; alkylating agents, antitumor antibiotics, platinum Drugs have slowed in recent years. Monoclonal antibody will be the biggest bright spot in the future growth of traditional Chinese medicine in the field of tumor-assisted drugs in the field of growth potential.

There are many anti-cancer drugs, and single varieties are mostly targeted at different segments of the disease. With the continued expansion of the market size of antitumor drugs and the increase in the number of existing varieties of existing drugs, as well as monoclonal drugs and other new drug research and development listed, heavyweight antitumor drugs ready to come out.

foreign market

Features: Monarch class king of gas potential unstoppable

Data: Top sellers TOP10 accounted for 3 seats, rituximab, trastuzumab, bevacizumab three drug sales totaling more than 200 billion dollars

From the global anti-cancer drug sales structure, monoclonal antibodies and protease inhibitors products dominate the market, both the entire antitumor drug market 65%, traditional drugs due to low prices led to lower sales accounted for. Global antitumor drug market is largely driven by innovative drugs, new drugs continue to emerge and promote, and the original product in the indications of the ever-expanding, making the rapid expansion of the market.

In 2014 the world's top ten best-selling brand drugs, the top 10 drug sales have reached more than 800 billion US dollars. Among them, cancer treatment drugs accounted for 3 seats, respectively, Roche's rituximab (rituximab), bevacizumab (Avastin) and trastuzumab (Herceptin), three drugs total sales of about 200 More than 100 million US dollars, accounting for the world's top 10 products nearly three percent share. Roche is a well-deserved leader in the field of antineoplastic drugs.

According to the world's best-selling drug statistics, in 2014, the global antitumor top 10 products medication amount of 46.6 billion US dollars, the amount of drugs in 2005 was 10.8 billion US dollars, 9-year market growth of 4.3 times, 2005 ~ 2014 compound annual growth rate of 19.9 %. Among them, rituximab, trastuzumab, bevacizumab is a heavy product with a sales of $ 7 billion; lenalidomide, imatinib, polyglycol Sales of nearly 5 billion US dollars of large products; bortezomib, pemetrexed, abitron, cetuximab for sales of 2 billion to 3 billion US dollars; over the same period the growth rate of more than 10.0% of the product song (12.4%), lenalidomide (14.1%), bortezomib (11.5%). In recent years, the new listing of products Abet Long than the same period increased by 24.1%, outstanding performance.

At present, the global anti-cancer drug is rapidly moving to the precise medical age, according to the US version of the precise medical plan, precision medicine is the key to gene sequencing, tumor, personalized. In the top 10 best-selling drug list in the world, there are three monoclonal antibody antineoplastic drugs, the current, the most mature medical field or targeted drug-based antitumor drug treatment based. Because monoclonal antibody anticancer drugs have less side effects and better targeting, monoclonal antibodies will continue to be the most important areas that lead to the development of antineoplastic drugs.